UK Biotech Investment Soars to £3.5bn in 2024, Reports BIA 01 Feb 2025: According to the BioIndustry Association’s (BIA) annual financing report, the UK biotech sector raised £3.5 billion in 2024, marking a 94% increase from the previous
Transforming Patient Care with Biomaterials: A conversation with Nihal Engin Vrana The intersection of biomaterials and personalised medicine is redefining the future of healthcare, unlocking new possibilities for treatment and recovery. From life-changing implantable devices to cutting-edge regenerative therapies, innovation in
Cultivated Meat and Market Disruption: A Conversation with Yash Mishra Cultivated meat, grown directly from animal cells without the need for traditional livestock farming, represents a paradigm shift in the global food industry. In a recent interview with Muhammad Younis,
Interview with Nava Whiteford: Insights into Nanopore Sequencing and Its Unique Edge In a recent interview with Nava Whiteford, Consultant at Whiteford Research Limited, we delved into what sets nanopore sequencing apart from other available sequencing technologies. He shared valuable insights with
Advancing Sustainable Agriculture - Interview with Nina Vinot on the Role of Microbiome Innovations In a recent interview, Nina Vinot, Director of Business Development at Cybele Agrocare, and Business Development, Bioprox Healthcare, discussed with Muhammad Younis how innovations in microbiome science are transforming agriculture.
UK and Switzerland Collaborate with £16 Million Investment in Joint Projects and Clinical Trials 09 December, 2024: In a major step forward for international scientific cooperation, Switzerland and the UK have updated their landmark science and research agreement, committing £16 million to support joint
Novo Nordisk to Establish New Production Facility in Denmark with $1.2 Billion Investment 16 December 2024: Novo Nordisk, a leading global healthcare company has unveiled plans to invest $1.2 bn in the construction of a brand-new production facility in Odense, Denmark. This
#LBS25 to Spotlight Advancements in Pharmaceutical Biotechnology, Digital Health, Medical Devices, Advanced Therapies, and More London, December 10: The second edition of the London Biotechnology Show (#LBS) continues to elevate its prestige with each passing day, as more renowned speakers and leading exhibitors join the
Interview with Behzad Mahdavi, Executive Chairman at OpenCell Technologies: Insights on Gene Therapies, Challenges and Solutions Gene therapy offers groundbreaking possibilities for treating genetic disorders, yet its journey to mainstream clinical use is hindered by key obstacles, involving safety, efficacy, delivery, and high manufacturing costs. In
From Discovery Park to Merck, Major Industry Players to Showcase at London Biotechnology Show 2025 London, November 4: Back for its second year, the London Biotechnology Show (#LBS25) gathers prominent biotech leaders, policymakers, and industry enthusiasts for an unparalleled showcase. Attendees can look forward to
UK Biotech Sector Achieves Impressive £808 Million in Q3 Funding October 21, 2024: The UK biotech sector achieved an impressive £808 million in funding during Q3 2024, successfully navigating challenging global market conditions and showcasing sustained investor confidence. This information
UK’s Life Science Sector Receives £279 Million Boost to Combat Health Issues October 14, 2024: The UK's leading life sciences sector is set to receive a £279 million boost to address major health challenges, as Lilly, the world's
IMU Biosciences Joins Innovative UK Research Consortium on Cancer Immunotherapy Responses October 07, 2024: IMU Biosciences, a biotechnology company at the forefront of systems-level immune profiling using AI to advance precision medicine, has announced its involvement in MANIFEST (Multiomic ANalysis of
Interview with Deon Neveling, CEO and Co-founder of Probipher Probiotics, long recognized for their health benefits in humans, are increasingly gaining attention for their potential to improve animal health and boost growth. In a recent interview, Deon Neveling, CEO
World’s First Ovarian Cancer Vaccine Being Developed in the UK October 4, 2024: The University of Oxford, recognised for its contributions to medical science, has secured funding up to £600,000 over the next three years from Cancer Research UK
